Small-Cap EPS Revision Stocks Surge: SEZL +14%, NVAX +13.6% Lead
Sezzle (SEZL) led today's EPS revision screen with a 14.0% gain to $128.64 after analysts raised its next-year EPS growth estimate to 27.3% and the company scheduled Q3 results, while Novavax (NVAX) jumped 13.6% to $12.75 on a 20.0pp upward revision to its 2027 EPS growth outlook. Rezolute (RZLT) added 12.7% to $4.87 after the FDA recommended a pre-BLA meeting for Ersodetug, and Fortuna Mining (FSM) and 20/20 Biolabs (AIDX) gained 7.9% and 8.6% respectively as the market validated early estimate revisions across healthcare and materials.
| Ticker | Sector | Detected | EPS Revision | Gain Since Detection |
|---|---|---|---|---|
| SEZL | Financial | 2026-10-06 | N/A | +14.0% |
| NVAX | Healthcare | 2026-10-07 | +20.0pp | +13.6% |
| RZLT | Healthcare | 2026-10-06 | +1.7pp | +12.7% |
| AIDX | Healthcare | 2026-10-05 | N/A | +8.6% |
| FSM | Basic Materials | 2026-10-07 | N/A | +7.9% |
Why did SEZL stock jump in October 2026?
SEZL jumped 14.0% (from $112.84 to $128.64) since October 6 after analysts raised its next-year EPS growth estimate to 27.3% and the company announced Q3 2026 results would be released on November 4.
The stock, already the best-performing consumer finance name of 2026 with a 77% year-to-date gain, found additional support from Sezzle's October 8 announcement that management will participate in five investor conferences through December, including BMO's Financials Conference and Citi's FinTech Conference. TD Cowen trimmed its price target on Sezzle as part of a broader Q3 earnings preview but kept the sell-side focus on the group's earnings power, and the market treated the revision and event calendar as confirmation of Sezzle's estimate momentum.
SEZL EPS revision history → · Screener snapshot from 2026-10-06 →
FAQ: SEZL
Why did SEZL stock jump in October 2026?
Sezzle gained 14.0% from $112.84 to $128.64 between October 6 and October 10 after its next-year EPS growth estimate was revised to 27.3% and the company set its Q3 earnings date for November 4.
What is Sezzle's EPS growth estimate for next year?
Sezzle's next-year EPS growth estimate stands at 27.3% as of the October 6, 2026 revision detected by our screener.
Is SEZL a buy after its 77% year-to-date rally?
Sezzle remains the best-performing consumer finance stock of 2026 with a 77% year-to-date gain, but TD Cowen lowered its price target in its October 7 Q3 earnings preview, suggesting valuation caution even as estimate momentum holds.
Why did NVAX stock jump in October 2026?
NVAX climbed 13.6% to $12.75 after analysts lifted its next-year EPS growth estimate by 20.0 percentage points to 97.3% on October 7, one of the largest upward revisions in the healthcare screen.
With no company-specific earnings news in the window, the move reflects renewed confidence in Novavax's path to profitability as cost cuts and partnership revenue reshape its forward earnings profile. The screener flagged the estimate jump at $11.22, and the market has since validated it with a double-digit gain, a rare magnitude for a stock whose 2027 EPS base remains small enough that percentage revisions swing violently.
NVAX EPS revision history → · Screener snapshot from 2026-10-07 →
FAQ: NVAX
Why did NVAX stock jump in October 2026?
Novavax rose 13.6% from $11.22 to $12.75 after its next-year EPS growth estimate was revised up by 20 percentage points to 97.3% on October 7, 2026.
What is NVAX's EPS growth estimate?
NVAX's next-year EPS growth estimate is now 97.3%, up from 77.3% before the October 7 revision, reflecting improving profitability expectations.
Is NVAX a buy after the rally?
The 20-point EPS estimate revision and subsequent 13.6% price gain suggest the market is buying the profitability story, though NVAX's low earnings base means future revisions will remain volatile.
Why did RZLT stock jump in October 2026?
RZLT surged 12.7% (from $4.32 to $4.87) after the FDA recommended a Type B pre-BLA meeting for its congenital hyperinsulinism drug Ersodetug on October 5, a regulatory green light that followed a Phase 3 miss.
The FDA reviewed additional glucose-monitoring data before suggesting the meeting, keeping a regulatory path alive for a therapy whose sunRIZE study failed its primary and key secondary endpoints. Analysts had already nudged next-year EPS growth estimates up 1.7 points to 27.3% on October 6, and the market's 12.7% gain shows investors are pricing a rerating on the possibility of a BLA filing despite the trial setback.
RZLT EPS revision history → · Screener snapshot from 2026-10-06 →
FAQ: RZLT
Why did RZLT stock jump in October 2026?
Rezolute jumped 12.7% from $4.32 to $4.87 after the FDA recommended a pre-BLA meeting for Ersodetug on October 5, even though the Phase 3 sunRIZE study missed its primary endpoints.
What caused RZLT's surge after its Phase 3 failure?
The FDA reviewed additional glucose-monitoring data and recommended Rezolute request a Type B pre-BLA meeting, signaling a potential path to filing for Ersodetug in congenital hyperinsulinism.
What is RZLT's EPS growth estimate?
RZLT's next-year EPS growth estimate was revised up to 27.3% from 25.6% on October 6, a 1.7 percentage point increase.
Why did AIDX stock jump in October 2026?
AIDX rose 8.6% (from $0.35 to $0.38) after our screener detected its next-year EPS growth estimate at 26.9% on October 5, with no company-specific earnings news driving the move.
The sub-$1 biotech trades on estimate momentum and low-float volatility, so a 26.9% forward growth reading was enough to attract speculative capital. With no catalysts in the window, the gain reflects positioning ahead of any potential pipeline or partnership updates rather than a confirmed fundamental event.
AIDX EPS revision history → · Screener snapshot from 2026-10-05 →
FAQ: AIDX
Why did AIDX stock jump in October 2026?
20/20 Biolabs gained 8.6% from $0.35 to $0.38 after the screener detected a next-year EPS growth estimate of 26.9% on October 5, 2026.
What is AIDX's EPS growth estimate?
AIDX's next-year EPS growth estimate is 26.9%, according to the October 5, 2026 screener reading.
Is AIDX a buy after its recent gain?
AIDX is a sub-$1 stock with no recent earnings news in the window, so the 8.6% move is speculative and tied to estimate momentum rather than a confirmed catalyst.
Why did FSM stock jump in October 2026?
FSM gained 7.9% to $10.92 after the screener detected a next-year EPS growth estimate of 25.1% on October 7, with no company-specific news in the window.
Fortuna Mining's move tracks the broader precious metals complex, where gold and silver prices have strengthened, lifting earnings expectations across the basic materials sector. The market confirmed the estimate revision with a steady 7.9% advance, suggesting investors are buying the earnings leverage rather than reacting to a single headline.
FSM EPS revision history → · Screener snapshot from 2026-10-07 →
FAQ: FSM
Why did FSM stock jump in October 2026?
Fortuna Mining rose 7.9% from $10.12 to $10.92 after the screener detected a next-year EPS growth estimate of 25.1% on October 7, 2026.
What is FSM's EPS growth estimate?
FSM's next-year EPS growth estimate is 25.1%, as flagged by the October 7, 2026 EPS revision screen.
Is FSM a buy after its recent gain?
FSM's 7.9% gain on a 25.1% forward EPS growth estimate reflects sector-wide strength in precious metals, but with no company-specific news, the move depends on continued commodity price support.
Today's gainers skew heavily toward small-cap healthcare and financials, where modest EPS estimate revisions are producing outsized price moves, signaling that investors are rewarding early-cycle earnings momentum in a market hungry for fundamental catalysts.
How We Identify These Stocks
We track daily changes in forward EPS estimates across thousands of US equities. When a stock's next-year earnings growth estimate is revised upward — confirmed by improvement in current-year estimates — it enters our watchlist. The stocks above were flagged on their detection dates and have since delivered the strongest price returns among all detected stocks.
Explore today's full screener →